[
1. She J et al. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clinical and Translational Medicine, 2020 9:19.
]Search in Google Scholar
[
2. Zheng J. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. International Journal of Biological Science,Vol.16, March 2020.10.7150/ijbs.45053709803032226285
]Search in Google Scholar
[
3. Guo YR et al. The origin, transmission and clinica therapies on coronavirus disease 2019 (COVID-19) outbreak- an update on the status. Military Medical Research, (2020) 7:11.10.1186/s40779-020-00240-0706898432169119
]Search in Google Scholar
[
4. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomedica, Vol.91, 2020.
]Search in Google Scholar
[
5. Date despre cazurile SARS-COV-2 in timp real, https://www.worldometers.info/coronavirus/.
]Search in Google Scholar
[
6. Streinu-Cercel A et al. SARS-CoV-2 in Romania- analysis of the first confirmed case and evolution of the pandemic in Romania in the first Three months; GERMS 10(2), June 2020, page 132-134.10.18683/germs.2020.1198
]Search in Google Scholar
[
7. Ooi EE, Low JG. Asymptomatic SARS-CoV-2 infection. The Lancet Infectious Diseases; June 12, 2020.10.1016/S1473-3099(20)30460-6
]Search in Google Scholar
[
8. Gran MC et al. The prevalence of symptoms in 24.410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLOS ONE, June 23, 2020.10.1371/journal.pone.0234765
]Search in Google Scholar
[
9. Dixon BE, Wools-Kaloustian KK,. Fadel WF, Dszynski TJ, Yiannoutsos C, Halverson PK, Menachemi H. Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study; PLOS ONE, March 24, 2021.10.1101/2020.10.11.20210922
]Search in Google Scholar
[
10. Verity R et al., Estimates of the severity of coronavirus disease 2019: a model- based analysis. The LANCET Infectious Diseases, March 30, 2020.
]Search in Google Scholar
[
11. Coronavirus Diseases 2019 (COVID-19) Treatment Guidelines, https://www.covid19treatmentguidelines.nih.gov/, Page 96-186.
]Search in Google Scholar
[
12. Ko WC et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents, 2020.10.1016/j.ijantimicag.2020.105933
]Search in Google Scholar
[
13. Kokic G, Hillen HS, Tegunov D, Dienemann C, Seitz F, Schmitzova J, Farnung L, Siewert A, Höbartner C, Cramer P. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir; Nature Communications, 2021.10.1101/2020.10.28.358481
]Search in Google Scholar
[
14. Wang Y et al. Remdesivir in adults with severe COVID-19: a randomized, duble-blind, placebo-controlled, multicenter trial; The Lancet, Vol 395, May 16, 2020.
]Search in Google Scholar
[
15. Simonis A, Theobald SJ, Fätkenheue Gr, Rybniker J, Malin JJ. A comparative analysis of remdesivir and other repurposed anti-virals against SARS-CoV-2; EMBO Molecular Medicine; 2021.10.15252/emmm.202013105
]Search in Google Scholar
[
16. Beigel JH et al. Remdesivir for the Treatment of Covid-19 – Final Report;The New England Journal of Medicine; Vol. 383, No. 19; November 5, 2020.10.1056/NEJMc202223632649074
]Search in Google Scholar
[
17 Humeniuk R, Mathias A, Kirby BJ, J Lutz JD, Cao H, Osinusi A, Babusis D, Porter D, Wei X, Ling J, Y. Reddy S, German P. Pharmacokinetic, Pharmacodynamic, and Drug-Intercation Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clinical Pharmacokinetics, 2021 60: 569-583.10.1007/s40262-021-00984-5800738733782830
]Search in Google Scholar
[
18. Ye ZW et al., Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. Emerging Microbes & Infections; 2021, 10:1, 291-304, DOI: 10.1080/22221751.2021.1885998.10.1080/22221751.2021.1885998791988533538646
]Search in Google Scholar
[
19. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accesed 14th June 2021, pag. 98.
]Search in Google Scholar
[
20. COVID-19 Clinical management, Living guidance, 21 January 2021, World Health Organization, https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1, pag. 44.
]Search in Google Scholar
[
21. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accesed 14th June 2021, pag. 107.
]Search in Google Scholar
[
22. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ; 2020; 369:m1432, doi: 10.1136/bmj.m1432.10.1136/bmj.m143232269046
]Search in Google Scholar
[
23. Malsonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, Nanick T, Pizzorno A, Lemaitre J, Goncalves A, Kahlaoui H et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature,Vol 585, 24 Setember.10.1038/s41586-020-2558-432698191
]Search in Google Scholar
[
24. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-COV-2 infection. CMAJ 2020 April 27; 192: E450-3. Doi: 10.1503/cmaj.200528.10.1503/cmaj.200528720720032269021
]Search in Google Scholar
[
25. Saghir et al. Chloroquine and Hydroxychloroquine for the Prevention and treatment o COVID-19: A Fiction, Hope or Hype? An Updated Review. Therapeutics and Clinical Risk Management, 2021:17.10.2147/TCRM.S301817809264333953559
]Search in Google Scholar
[
26. Liu et al. Hydroxychloroquine, a less toxic derivate of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 2020, 6: 16.10.1038/s41421-020-0156-0707822832194981
]Search in Google Scholar
[
27 Gyselinck I, Janssens W, Verhamme P, Vos R. Rationale for azithromycin in COVID-19: an overview of existing evidence. BMJ Open Resp Res 2021; 8:e000806. Doi:10.1136/bmjresp-2020-000806.10.1136/bmjresp-2020-000806781196033441373
]Search in Google Scholar
[
28. Echeverria-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio Cusco M, Ferrandez O, Horcajada JP, Grau S. Azithromycin in the treatment of COVID-19: a review. Expert Review of Anti-infective Therapy, 19:2, 147-163, DOI: 10.1080/14787210.2020.1813024; Oct 2020.
]Search in Google Scholar
[
29. What is the status of azithromycin in the treatment of coronavirus disease 2019 (COVID-19)?; Medscape Drugs& Diseases, Updated: Jul,2020.
]Search in Google Scholar
[
30 Schwarts RA, Suskind RM. Azithromycin and COVID-19: Prompt early use at forst signs of this infection in adults and children, an approach worthy of consideration. Dermatologic Therapy. 2020; 33:e13785.10.1111/dth.13785730056332510734
]Search in Google Scholar
[
31. Hayek S. Azithromycin for Suspected COVID-19 in People at Increased Risk. Lancet 2021 Mar 4.
]Search in Google Scholar
[
32. Statement from the Chief Investigators of the Randmised Evaluation of Covid-19 ThERapy (RECOVERY) Trial on azithromycin, 14 December 2020; www.recoverytrial.net.
]Search in Google Scholar
[
33. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accesed 14th June 2021, pag. 124-125.
]Search in Google Scholar
[
34. Ogbru O, JMarks JW. Lopinavir and ritonavir (Kaletra):Potential COVID-19 Drug. MedicineNet, August 2020.
]Search in Google Scholar
[
35. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accesed 14th June 2021, pag. 140.
]Search in Google Scholar
[
36. A Trail of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19; Cao et al.; The New England of Medicine; vol.382, No.19; May 7, 2020.10.1056/NEJMc200804332369281
]Search in Google Scholar
[
37 Ye et al. Clinical efficacy of lopinair/ritonavir in the treatment of Coronavirus disease 2019. Europnean Review for Medical and Pharmacological Science; 2020; 24:3390-3396.
]Search in Google Scholar
[
38. Dalerba P, Levin B, Thompson JL. A Trial of Lopinavir-Ritonavir in Covid-19. The NEJM; Correspondence, May 5, 2020, NEJM.org.
]Search in Google Scholar
[
39. RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label,platform trial. The Lancet; Vol 396, October 24, 2020.
]Search in Google Scholar
[
40. COVID-19 Clinical management, Living guidance, 21 January 2021, World Health Organization, https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1, pag. 44.
]Search in Google Scholar
[
41. Peng Q et al. Structural basis of SARS-CoV-2 polymerase inhibitor by Favipiravir. Innovation (NY; 2021 Feb 28; 2 (1):100080; doi: 10.1016/j.xinn.2021.100080.10.1016/j.xinn.2021.100080
]Search in Google Scholar
[
42. Driouich et al. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model; Nature Communication; 19 March 2021.10.1101/2020.07.07.191775
]Search in Google Scholar
[
43. Cai O et al. Experimental Tratment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering 6 (2020) 1192-1198.10.1016/j.eng.2020.03.007
]Search in Google Scholar
[
44. Erdem HA et al. Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. Turkish Journal of Medical Sciences; 2021, 51.10.3906/sag-2008-33
]Search in Google Scholar
[
45. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accesed 14th June 2021, pag. 149-150.
]Search in Google Scholar
[
46. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accesed 14th June 2021, pag. 162-163.
]Search in Google Scholar
[
47. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accesed 14th June 2021, pag. 180, 211.
]Search in Google Scholar
[
48. Prescott HC; Rice TW. Corticosteroids in COVID-19 ARDS Evidence and Hope During the Pandemic. JAMA; Vol 324 No 13; October 6, 2020.10.1001/jama.2020.16747
]Search in Google Scholar
[
49. Shuto H, Komiya K, Yamasue M, Uchida S, Ogura T, Mukae H, Tateda K, Hiramatsu K, Kadota JI. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. Scientific Reports; Nature research; 2020, 10:20935.10.1038/s41598-020-78054-2
]Search in Google Scholar
[
50. Johns M, George S, Taburyanskaya M, Poon YK. A Review of the Evidence for Corticosteroids in COVID-19. Journal of Pharmacy Practice XX; 2020.10.1177/0897190021998502
]Search in Google Scholar
[
51. Ssekandi AM, O Sserwanja, Olal E, Kawuki J, MB Adam. Costicosteroids Use in Pregnant Women with COVID-19: Recommendations from Available Evidence. Journal of Multidisciplinary Healthcare; 2021:14, 659-663.10.2147/JMDH.S301255
]Search in Google Scholar
[
52. Lopez-Medrano F et al. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study. International Journal of Infectious Diseases; 2021, 487-494.10.1016/j.ijid.2021.02.099
]Search in Google Scholar
[
53. Cano EJ et al. Impact of Corticosteroids in Coronvirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. CHEST; 2021, 159 (3): 1019-1040.10.1016/j.chest.2020.10.054
]Search in Google Scholar
[
54. Mishra GP, Mulani J. Corticosteroids for COVID-19: the search for an optimum duration of therapy. The Lancet; Vol 9, January 2021.10.1016/S2213-2600(20)30530-0
]Search in Google Scholar
[
55. Ho KS et al. Impact of corticosteroids in hospitalized COVID-19 patients. MBJ Opne Respiratory Research; 2021; 8:e000766; doi:10.1136/bmjresp-2020-000766.10.1136/bmjresp-2020-000766
]Search in Google Scholar
[
56. Ranjbar K et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple blinded randomized controlled trial. BMJ Infectious Diseases; 2021 21:337.10.1186/s12879-021-06045-3
]Search in Google Scholar
[
57 COVID-19 Clinical management, Living guidance, 21 January 2021, World Health Organization, https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1, pag. 44.
]Search in Google Scholar
[
58. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Resp j; 2020, 55: 2001009.10.1183/13993003.01009-2020
]Search in Google Scholar
[
59. Matsuyama S et al. The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting th Viral Replication-Transcription Complex in Cultured Cells. Journal of Virology; Vol 95, Issue 1; January 2021; e01648-20.10.1128/JVI.01648-20
]Search in Google Scholar
[
60. Lipworth B, Kuo CRW, S Lipworth, Chan R. Inhaled Corticosteroids and COVID-19. American Journal of Respiratory and Critical Care Medicine; Correspondence, Vol 202, No 6; September 15 2020.10.1164/rccm.202005-2000LE
]Search in Google Scholar
[
61. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accesed 14th June 2021, pag. 213.
]Search in Google Scholar
[
62. King A et al. Anakinra in COVID-19: important considerations for clinical trials. The Lancet; Vol 2, July 2020.10.1016/S2665-9913(20)30160-0
]Search in Google Scholar
[
63. Khan AR, Soneja M, George N, Wig N. Anakinra for severe forms of COVID-19. The Lancet; Vol 2; October 2020.10.1016/S2665-9913(20)30271-X
]Search in Google Scholar
[
64. Huet T et al. Anakinra for severe forms of COVID-19: a cohort study. The Lancet; Vol 2, July 2020.10.1016/S2665-9913(20)30164-8
]Search in Google Scholar
[
65. Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, Justet A. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia; case series. BMJ; Vol 79, No 10; October 2020.10.1136/annrheumdis-2020-217706
]Search in Google Scholar
[
66. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accesed 14th June 2021, pag. 220.
]Search in Google Scholar
[
67. Morena V et al. Off-label use of tocilizumb for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. European Journal of Internal Medicine; 76, 2020, 36-42.10.1016/j.ejim.2020.05.011
]Search in Google Scholar
[
68. Jordan et al. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia. Clinical Infectious Diseases; 2020:XX.10.1093/cid/ciaa812
]Search in Google Scholar
[
69 Guaraldi G et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet; Vol 2, August 2020.
]Search in Google Scholar
[
70. Wei Q et al. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infectious Diseases of Povery; 2021, 10:71.10.1186/s40249-021-00857-w
]Search in Google Scholar
[
71. Kulanthaivel S ET AL. Reviews on Recent Clinical Trials: Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Citokine Storm: A Narrative Review. Rev Recent Clin Trials; 2021; 16 (2): 138-145.10.2174/1574887115666200917110954
]Search in Google Scholar
[
72. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accesed 14th June 2021, pag. 238-240.
]Search in Google Scholar
[
73. Kurian SJ, AuR B, Alvi MA et al.; Correlations between COVID-19 cases and Google Trends data in the United States: A state-by-state analysis; Mayo Clin Proc.; 2020; 95 (11): 2370-2381.10.1016/j.mayocp.2020.08.022
]Search in Google Scholar
[
74. Talasaz et al. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. Journal of the American College of Cardology; ardology; Vol 77, No 15, 2021.10.1016/j.jacc.2021.02.035
]Search in Google Scholar
[
75. Patolia SK, Mosenifar Z. What is the role of anticoagulation in the treatment of COVID-19?. Medscape; Jan 12, 2021.
]Search in Google Scholar
[
76. Cucker A et al. American Society of Hematology 2021 guidelines of the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Advances; Vol 5, No 3, 9 February 2021.
]Search in Google Scholar
[
77. Lopes RD et al. Therapeutic versus prophylactic anticoagulantion for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an opne-label, multi-center, randomized, controlled trial. The Lancet; Vol 397, June 12 2021.
]Search in Google Scholar
[
78. Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Reviews; 47, 2021 100761.10.1016/j.blre.2020.100761
]Search in Google Scholar
[
79. COVID-19 Clinical management, Living guidance, 21 January 2021, World Health Organization, https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1, pag. 40.
]Search in Google Scholar
[
80. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accesed 14th June 2021, pag. 267.
]Search in Google Scholar
[
81. Fisher et al. Molnupiravir, an oral antiviral treatment for COVID-19; MedRxiv., Preprint., Jun 17 2021.
]Search in Google Scholar
